Literature DB >> 20479236

Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice.

Masao Kakoki1, Kelli A Sullivan, Carey Backus, John M Hayes, Sang Su Oh, Kunjie Hua, Adil M H Gasim, Hirofumi Tomita, Ruriko Grant, Sarah B Nossov, Hyung-Suk Kim, J Charles Jennette, Eva L Feldman, Oliver Smithies.   

Abstract

An insertion polymorphism of the angiotensin-I converting enzyme gene (ACE) is common in humans and the higher expressing allele is associated with an increased risk of diabetic complications. The ACE polymorphism does not significantly affect blood pressure or angiotensin II levels, suggesting that the kallikrein-kinin system partly mediates the effects of the polymorphism. We have therefore explored the influence of lack of both bradykinin receptors (B1R and B2R) on diabetic nephropathy, neuropathy, and osteopathy in male mice heterozygous for the Akita diabetogenic mutation in the insulin 2 gene (Ins2). We find that all of the detrimental phenotypes observed in Akita diabetes are enhanced by lack of both B1R and B2R, including urinary albumin excretion, glomerulosclerosis, glomerular basement membrane thickening, mitochondrial DNA deletions, reduction of nerve conduction velocities and of heat sensation, and bone mineral loss. Absence of the bradykinin receptors also enhances the diabetes-associated increases in plasma thiobarbituric acid-reactive substances, mitochondrial DNA deletions, and renal expression of fibrogenic genes, including transforming growth factor beta1, connective tissue growth factor, and endothelin-1. Thus, lack of B1R and B2R exacerbates diabetic complications. The enhanced renal injury in diabetic mice caused by lack of B1R and B2R may be mediated by a combination of increases in oxidative stress, mitochondrial DNA damage and over expression of fibrogenic genes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20479236      PMCID: PMC2890475          DOI: 10.1073/pnas.1005144107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

1.  cAMP-dependent tyrosine phosphorylation of subunit I inhibits cytochrome c oxidase activity.

Authors:  Icksoo Lee; Arthur R Salomon; Scott Ficarro; Isabella Mathes; Friedrich Lottspeich; Lawrence I Grossman; Maik Hüttemann
Journal:  J Biol Chem       Date:  2004-11-19       Impact factor: 5.157

2.  Angiotensinogen and angiotensin-converting enzyme gene copy number and angiotensin and bradykinin peptide levels in mice.

Authors:  Theodora Alexiou; Wee Ming Boon; Derek A Denton; Robert Di Nicolantonio; Lesley L Walker; Michael J McKinley; Duncan J Campbell
Journal:  J Hypertens       Date:  2005-05       Impact factor: 4.844

3.  Bone mineral density in patients with type 1 and type 2 diabetes.

Authors:  J T Tuominen; O Impivaara; P Puukka; T Rönnemaa
Journal:  Diabetes Care       Date:  1999-07       Impact factor: 19.112

4.  Polymorphism of the angiotensin-converting enzyme (ACE) gene in patients with thrombotic brain infarction.

Authors:  Y Doi; M Yoshinari; H Yoshizumi; S Ibayashi; M Wakisaka; M Fujishima
Journal:  Atherosclerosis       Date:  1997-07-25       Impact factor: 5.162

5.  ACE gene polymorphism and proliferative retinopathy in type 1 diabetes: results of a case-control study.

Authors:  D Rabensteiner; H Abrahamian; K Irsigler; K M Hermann; H P Kiener; G Mayer; A Kaider; R Prager
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

6.  Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction.

Authors:  Jiang Xu; Oscar A Carretero; Ying Sun; Edward G Shesely; Nour-Eddine Rhaleb; Yun-He Liu; Tang-Dong Liao; James J Yang; Michael Bader; Xiao-Ping Yang
Journal:  Hypertension       Date:  2005-02-07       Impact factor: 10.190

7.  Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension.

Authors:  B Hocher; C Thöne-Reineke; P Rohmeiss; F Schmager; T Slowinski; V Burst; F Siegmund; T Quertermous; C Bauer; H H Neumayer; W D Schleuning; F Theuring
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

8.  Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial.

Authors:  R A Malik; S Williamson; C Abbott; A L Carrington; J Iqbal; W Schady; A J Boulton
Journal:  Lancet       Date:  1998 Dec 19-26       Impact factor: 79.321

9.  Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin.

Authors:  R H Pichler; N Franceschini; B A Young; C Hugo; T F Andoh; E A Burdmann; S J Shankland; C E Alpers; W M Bennett; W G Couser
Journal:  J Am Soc Nephrol       Date:  1995-10       Impact factor: 10.121

10.  Endothelium-dependent relaxations mediated by inducible B1 and constitutive B2 kinin receptors in the bovine isolated coronary artery.

Authors:  G R Drummond; T M Cocks
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

View more
  50 in total

1.  Local bone interaction between renin-angiotensin system and kallikrein-kinin system in diabetic rat.

Authors:  Yong Li; Guang-Si Shen; Chen Yu; Guang-Fei Li; Jun-Kang Shen; You-Jia Xu; Jian-Ping Gong
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  Inflammation and Immunity Pathways Regulate Genetic Susceptibility to Diabetic Nephropathy.

Authors:  Susan B Gurley; Sujoy Ghosh; Stacy A Johnson; Kengo Azushima; Rashidah Binte Sakban; Simi E George; Momoe Maeda; Timothy W Meyer; Thomas M Coffman
Journal:  Diabetes       Date:  2018-07-31       Impact factor: 9.461

Review 3.  Mouse models of diabetic neuropathy.

Authors:  Phillipe D O'Brien; Stacey A Sakowski; Eva L Feldman
Journal:  ILAR J       Date:  2014

4.  The identification of gene expression profiles associated with progression of human diabetic neuropathy.

Authors:  Junguk Hur; Kelli A Sullivan; Manjusha Pande; Yu Hong; Anders A F Sima; Hosagrahar V Jagadish; Matthias Kretzler; Eva L Feldman
Journal:  Brain       Date:  2011-09-16       Impact factor: 13.501

Review 5.  A new perspective on mechanisms governing skeletal complications in type 1 diabetes.

Authors:  Zeynep Seref-Ferlengez; Sylvia O Suadicani; Mia M Thi
Journal:  Ann N Y Acad Sci       Date:  2016-08-29       Impact factor: 5.691

6.  Protective role of AT(2) and B(1) receptors in kinin B(2)-receptor-knockout mice with myocardial infarction.

Authors:  Jiang Xu; Oscar A Carretero; Liping Zhu; Edward G Shesely; Nour-Eddine Rhaleb; Xiangguo Dai; Luchen Wang; James J Yang; Xiao-Ping Yang
Journal:  Clin Sci (Lond)       Date:  2013-01       Impact factor: 6.124

7.  Kinin B1 receptor enhances the oxidative stress in a rat model of insulin resistance: outcome in hypertension, allodynia and metabolic complications.

Authors:  Jenny Pena Dias; Sébastien Talbot; Jacques Sénécal; Pierre Carayon; Réjean Couture
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

Review 8.  Role of plasma kallikrein in diabetes and metabolism.

Authors:  E P Feener; Q Zhou; W Fickweiler
Journal:  Thromb Haemost       Date:  2013-05-16       Impact factor: 5.249

9.  Exacerbation of DSS-induced colitis in mice lacking kinin B(1) receptors through compensatory up-regulation of kinin B(2) receptors: the role of tight junctions and intestinal homeostasis.

Authors:  R Marcon; R F Claudino; R C Dutra; A F Bento; E C Schmidt; Z L Bouzon; R Sordi; R L T Morais; J B Pesquero; J B Calixto
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

10.  IL-4 and IL-13 inhibit IL-1β and TNF-α induced kinin B1 and B2 receptors through a STAT6-dependent mechanism.

Authors:  P P C Souza; A B Brechter; R I Reis; C A S Costa; P Lundberg; U H Lerner
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.